Trends in inpatient antiparkinson drug use in the USA, 2001–2012

Pergolide Associated Cardiac Valvulopathy Based on Ontario Administrative Data

(2014) Cindy Zadikoff et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients

(2014) Santiago Perez-Lloret et al.   Expert Opinion On Drug Safety

Reasons for hospitalization in Parkinson's disease: A case-control study

(2014) Massimiliano Braga et al.   PARKINSONISM & RELATED DISORDERS

Prescribing Pattern of Anti-Parkinson Drugs in Japan: A Trend Analysis from 2005 to 2010

(2014) Sachiko Nakaoka et al.   PLoS One

Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs

(2014) Thomas J. Moore et al.   JAMA Internal Medicine

Antiparkinson Drug Use and Adherence in Medicare Part D Beneficiaries With Parkinson’s Disease

(2013) Yu-Jung Wei et al.   CLINICAL THERAPEUTICS

Risk of Heart Failure Associated with Dopamine Agonists: A Nested Case–Control Study

(2013) P. H. Hsieh et al.   DRUGS & AGING

Parkinson Disease in Long Term Care Facilities: A Review of the Literature

(2013) Nico J. Weerkamp et al.   Journal of the American Medical Directors Association

Disparities in deep brain stimulation surgery among insured elders with Parkinson disease

(2013) A. W. Willis et al.   NEUROLOGY

Reasons for Parkinson's disease admissions in a large inner city hospital

(2013) A. Arasalingam et al.   PARKINSONISM & RELATED DISORDERS

Impulse Control and Related Disorders in Parkinson’s Disease

(2012) Daniel Weintraub et al.   Neurodegenerative Diseases

Neurologist-associated reduction in PD-related hospitalizations and health care expenditures

(2012) A. W. Willis et al.   NEUROLOGY

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

(2011) Klaus Seppi et al.   MOVEMENT DISORDERS

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

(2011) Susan H. Fox et al.   MOVEMENT DISORDERS

Neuroprotective Role of Dopamine Agonists

(2011) Maria Trinidad Herrero et al.   NEUROLOGIST

Does levodopa accelerate the pathologic process in Parkinson disease brain?

(2011) L. Parkkinen et al.   NEUROLOGY

Neurologist care in Parkinson disease: A utilization, outcomes, and survival study

(2011) A. W. Willis et al.   NEUROLOGY

Utilization of anti-Parkinson drugs in Australia: 1995-2009

(2011) Samantha A Hollingworth et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Dopamine agonist use and the risk of heart failure

(2011) Christel Renoux et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Current approaches to the treatment of Parkinson’s disease

(2011) Joseph Jankovic   Neuropsychiatric Disease and Treatment

Prescribing patterns of antiparkinsonian agents in Europe

(2010) Mário Miguel Rosa et al.   MOVEMENT DISORDERS

Geographic and Ethnic Variation in Parkinson Disease: A Population-Based Study of US Medicare Beneficiaries

(2010) Allison Wright Willis et al.   NEUROEPIDEMIOLOGY

Trials of neuroprotective therapies for Parkinson’s disease: Problems and limitations

(2010) Raúl de la Fuente-Fernández et al.   PARKINSONISM & RELATED DISORDERS

Treatment disparities in Parkinson's disease

(2009) Nabila Dahodwala et al.   ANNALS OF NEUROLOGY

Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review

(2009) Malcolm Steiger et al.   JOURNAL OF NEURAL TRANSMISSION

The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease

(2008) Anthony H.V. Schapira   MOVEMENT DISORDERS

Current status of symptomatic medical therapy in Parkinson’s disease

(2008) Stewart A. Factor   Neurotherapeutics

Prescribing pattern of anti-Parkinson drugs in Southern Italy: Cross-sectional analysis in the years 2003–2005

(2008) Gianluca Trifirò et al.   PARKINSONISM & RELATED DISORDERS